Skip to content
Resources > Reports

State of Generative AI & Market Intelligence Report 2023

Understanding how Generative AI is changing how teams conduct company research, gather market and competitive intelligence, and construct corporate strategies is critical as we head into 2024. To quickly get up to speed on how genAI technology is transforming market intelligence research, download our 2023 State of Generative AI & Market Intelligence Report. The report provides:

  • Projections on genAI usage in 2024 and beyond
  • The biggest perceived concerns of genAI usage
  • How to quantify the value of access to genAI tools for market intelligence research

Featuring the insights of 500+ respondents who conduct company and industry research across the globe, the State of Generative AI & Market Intelligence report is an essential asset to inform your team’s 2024 planning—and to keep you on the bleeding edge of industry trends in terms of AI adoption and whether your organization is an early adopter (or not).

Download our State of Generative AI & Market Intelligence Reportnow to read about the appetites, opinions, and habits of knowledge workers who are already under the thrall of AI.

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.